T1	Outcomes 896 1086	included histologic assessment of bowel biopsies and assessment of serologic markers of inflammatory bowel disease (IBD), fecal calprotectin levels, and polymorphisms in immune-related genes
T2	Outcomes 1195 1279	levels to enteric flora, inflammatory cell infiltration into gastrointestinal mucosa
T3	Outcomes 1285 1371	increased fecal calprotectin associated with diarrhea and clinical evidence of colitis
T4	Outcomes 1567 1612	prevent ipilimumab-induced bowel inflammation
T5	Outcomes 1697 1705	diarrhea
